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Abstract
Background: Plasmablasts and plasma cells play a key role in many autoimmune diseases, such as rheumatoid
arthritis (RA) and systemic lupus erythematosus (SLE). This study was undertaken to evaluate the potential of
targeting CD38 as a plasma cell/plasmablast depletion mechanism by daratumumab in the treatment of patients
with RA and SLE.
Methods: RNA-sequencing analysis of synovial biopsies from various stages of RA disease progression, flow
cytometry analysis of peripheral blood mononuclear cells (PBMC) from patients with RA or SLE and healthy donors,
immunohistochemistry assessment (IHC) of synovial biopsies from patients with early RA, and ex vivo immune cell
depletion assays using daratumumab (an anti-CD38 monoclonal antibody) were used to assess CD38 as a
therapeutic target.
Results: We demonstrated that the plasma cell/plasmablast-related genes CD38, XBP1, IRF4, PRDM1, IGJ and TNFSF13B
are significantly up-regulated in synovial biopsies from patients with arthralgia, undifferentiated arthritis (UA), early RA
and established RA as compared to healthy controls and control patients with osteoarthritis. In addition, the highest
CD38 expression was observed on plasma cells and plasmablasts compared to natural killer (NK) cells, classical dendritic
cells (DCs), plasmacytoid DCs (pDCs) and T cells, in blood from healthy controls and patients with SLE and RA.
Furthermore, IHC showed CD38 staining in the same region as CD3 and CD138 staining in synovial tissue biopsies
from patients with early RA. Most importantly, our data show for the first time that daratumumab effectively depletes
plasma cells/plasmablasts in PBMC from patients with SLE and RA in a dose-dependent manner ex vivo.
Conclusion: These results indicate that CD38 may be a potential target for RA disease interception and daratumumab
should be evaluated clinically for the treatment of both RA and SLE.
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Background
Autoantibodies play an important role in the pathogen-
esis of many autoimmune diseases, including rheuma-
toid arthritis (RA) [1] and systemic lupus erythematosus
(SLE) [2]. Classical autoantibodies target the tissue dir-
ectly or via formation of immune complexes [3]. Short-
lived plasmablasts and plasma cells and long-lived
plasma cells can generate high titers of autoantibodies
upon activation. Long-lived plasma cells reside in bone
marrow and inflammatory tissue niches and produce
copious amounts of autoantibodies independent of B cell
activation. Studies have shown an increased number of
plasmablasts or ratio of plasmablast/B cells in the blood
of patients with active SLE [4]. Although the bone mar-
row provides the survival niche for long-lived plasma
cells [5, 6], inflammatory tissues bear high B cell-
activating factor (BAFF) and a proliferation-inducing lig-
and (APRIL), maintain long-lived plasma cell survival,
and thus contribute to the autoantibody secretion in in-
flammatory joints in patients with RA [7] and nephritic
kidneys in NZB/W mice [8]. Different therapeutic agents
have been developed to target antibody production in
autoimmune diseases. Rituximab (anti-CD20) and beli-
mumab (anti-BLyS) prevent short-lived plasmablasts
from proliferating and reduce autoantibody production
to some degree. However, non-proliferative long-lived
plasma cells are not susceptible to this effect. Short-term
treatment with the proteasome inhibitor bortezomib
followed by B-cell target therapy (anti-CD20) decreases
anti-dsDNA-secreting plasma cells and delays the devel-
opment of nephritis in NZB/W mice [9]. Clinical studies
show that bortezomib depletes plasma cells and amelio-
rates disease in patients with refractory SLE [10, 11].
Inhibition of plasma cell survival via blockade of BAFF
and APRIL has also been tested. Atacicept (soluble
TACI-Ig) has shown no clinical response in patients with
RA [12]. Though atacicept at a lower dose (75 mg) was
proved non-effective in prevention of flares in SLE in pa-
tients with moderate to severe disease, a higher dose
(150 mg) proved beneficial on flare rate and time to first
flare. Unfortunately, the trial was terminated due to two
deaths caused by pneumonia in that study group [12].
Aside from the strategies mentioned above, it is worth-
while to determine if plasma-cell-specific targets may
prove more efficacious in the treatment of autoimmune
diseases, such as RA and SLE.
CD38 is a type II glycoprotein highly expressed on
plasma cells, memory B cells and multiple myeloma
(MM) cells [13]. Daratumumab, a depleting monoclonal
anti-CD38 antibody, has been approved for the treat-
ment of patients with MM [14, 15]. Plasma cell deple-
tion in the bone marrow has been observed in patients
with MM treated with daratumumab [16]. It is therefore
reasonable to hypothesize that CD38 can be a target for
the treatment of autoimmune diseases by depleting
plasma cells specifically. Previous studies have shown
CD38 expression in the synovial biopsies of patients with
established RA [17]. A comprehensive analysis of CD38
expression on various immune cells in patients with
autoimmune diseases could facilitate the dosing possibil-
ity of depleting only plasmablasts and plasma cells
without affecting other potentially beneficial cells. Fur-
thermore, despite the fact that anti-citrullinated protein
antibodies (ACPA) may already exist in pre-RA stages,
no studies have analyzed the dynamic role that plasma
cells and plasmablasts may play during RA disease pro-
gression, namely from arthralgia to undifferentiated
arthritis (UA), early RA and established RA. It is possible
that targeting CD38 at the pre-disease stage could
achieve greater disease suppression in patients with RA
and SLE. Therefore, in this study, we investigated the
potential of targeting CD38 at various stages of RA
progression. Most importantly, for the first time, we
evaluated the efficacy of a U.S. Food and Drug
Administration-approved cancer drug targeting CD38,
daratumumab, in depleting plasma cells/plasmablasts ex
vivo in PBMC from patients with RA and SLE, to pro-
vide a rationale for clinical trials of daratumumab in pa-
tients with RA and SLE.
Herein, RNA sequencing (RNA-Seq) showed that vari-
ous plasma cell/plasmablast-related genes are signifi-
cantly up-regulated in pre-disease (arthralgia and UA)
and RA (early and established) synovial tissue biopsies
compared to counterpart healthy donors or patients with
osteoarthritis (OA). Furthermore, the highest CD38 ex-
pression in peripheral blood was observed on plasma
cells and plasmablasts, followed by NK cells, pDCs, a
regulatory T cell (Treg) subpopulation and naïve T cells
in healthy donors and patients with SLE and with RA.
Immunohistochemistry assessment showed the presence
of plasma cells and T cells in the synovial biopsies from
patients with early RA. Finally, we demonstrated that
daratumumab depletes plasma cells/plasmablasts in a
dose-dependent manner ex vivo.
Methods
Human subjects
The human donors (healthy controls and people with OA,
arthralgia, UA, early RA and established RA) in this study
have been described previously [18]. Briefly, synovial bi-
opsy specimens from healthy and donors with OA were
obtained from a group of patients attending a sports
medicine facility with knee pain. Healthy subjects were de-
fined as those who had no arthritis, cartilage damage or
synovitis on knee arthroscopy. Donors with OA had clin-
ical history and/or examination findings suggestive of OA
in addition to supportive arthroscopic findings. The aver-
age age of healthy donors was 35.2 years. The average age
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of donors with OA was 49.0 years. There were 13
women (59.1%) and 9 men (40.9%). Patients with arth-
ralgia (n = 10) were subjects with symptoms of aches
and pains, without clinical signs of synovitis or signifi-
cantly raised C-reactive protein (CRP) (mean = 4.49 mg/l)
at first assessment, but with positive circulating
rheumatoid factor (RF+) and ACPA. There were eight
women and two men, and the mean age was 51.6 years
(range 34–66 years). Patients with undifferentiated
arthritis/inflammatory arthritis (UA/IA) (n = 6) were
defined as subjects presenting with clinical signs of
synovitis, but who did not meet the 2010 American
College of Rheumatology (ACR) criteria for RA. All six
patients were female, the mean age was 46 years, and
they had significantly raised CRP (mean = 17.66 mg/l).
Early RA (n = 57) was defined as within 12 months of
disease diagnosis without prior small or large molecule
disease modifying anti-rheumatic drugs (DMARDs)
usage (mean disease duration = 5 months). Early RA
synovial tissue biopsies were collected from two differ-
ent cohorts of patients identified at Flinders University
and Queen Mary University of London. There were 33
women and 22 men, and the mean age was 55.9 years.
Established RA (n = 95; disease duration >1 year) synovial
tissue biopsies were collected from two different cohorts
of patients identified at Queen Mary University of London
and St. Vincent’s Hospital. The average disease duration in
this patient population was 68 months. The average age in
the group was 54.0 years. All patients with established RA
had received small molecule DMARDs or anti-TNFα
treatments. More details about the clinical characteristics
of these subjects included in this analysis can be found in
a report of a previous study [18].
PBMC samples for CD38 expression analysis from pa-
tients with SLE and RA and from healthy donors were ac-
quired from Bioreclamation (Westbury, NY, USA) and
Precision for Medicine (Frederick, MD, USA). All donors
with SLE were clinically active at the most recent visit into
the clinic before the blood draw and under standard of care
treatments, including prednisone, benlysta (n = 1), rituxi-
mab (n = 1) and other small molecule therapeutics. One
patient was treatment-naïve at the time of the blood draw.
The mean SLE disease activity index (SLEDAI) scores in
these subjects was 18.7 (range 6–32), which indicates active
disease. All donors with RA were clinically active at the
time of blood draw and had received various DMARD
treatments. The biologic treatments included Orencia
(n = 1), Simponi (n = 1), Simponi Aria (n = 1), Humira
(n = 1), and Enbrel (n = 3). All subjects had received small
molecule DMARD treatments before the blood draw.
All protocols for collecting synovial biopsies and
blood/serum were approved by the Institutional Review
Board. All patients signed the consent form for partici-
pating in the study.
RNA-Seq gene expression analysis
RNA-Seq analysis was performed on the same synovial
biopsies using the same algorithm as reported previously
and the RNA-Seq data were deposited in the Gene
Expression Omnibus (GEO) database as part of a previ-
ous study [GEO:GSE89408] [18].
Total RNA was extracted from frozen synovial biopsies
from patients with RA and only RNA samples that passed
quality control by an Agilent Bioanalyzer were further an-
alyzed. RNA-Seq was performed by Q2 Solutions
(Morrisville, NC, USA). Sequencing libraries were pre-
pared using TruSeq Stranded Total RNA RiboZero proto-
col from Illumina. Libraries were pooled and sequenced
with an Illumina HiSeq 2000 with paired-end 100-bp flow
cells. FastQC was used to evaluate raw read quality.
Reads were trimmed for adaptors and sequence qual-
ity. The average number of clusters (post-trimming) per
sample was 8.9 × 107. Trimmed reads were aligned to
the human b37.3 reference genome using the STAR v2.4
aligner [19]. Aligned reads were quantified using RSEM
v1.2.14 algorithm [20] with UCSC transcriptome model
(accessed on 17 March 2014) that included long
intergenic non-coding RNAs (lincRNAs) from Ensembl
v75. This transcriptome model has a total of 34,495
genes and 88,933 isoforms. Aligned data were evaluated
for quality using several metrics (e.g., mapping rate,
coverage) and visually inspected for deviation from the
population across multiple metrics and principal compo-
nents analysis. Statistical testing of RNA-Seq data was
performed in R with the “limma” package [21]. Counts
were converted to log2 counts per million, quantile nor-
malized and precision weighted. A linear model was fit-
ted to each gene, and empirical Bayes moderated t
statistics were used to assess differences in expression.
Fluorescence-activated cell sorting (FACS) analysis
PBMC samples were analyzed in three different staining
panels for CD38 expression as follows: Panel 1: CD38-
FITC, CD14-PE, HLA-DR-PerCPCy5.5, CD11b-PECy7,
CD33-APC, BDCA2-VioBlue, CD16-BV510, Lineage
(CD3/CD8/CD4/CD19)-BV605, CD45-BV650, CD11c-
BV711 and CD56-BV786. Panel 2: CD38-FITC, CD62L-
PE, CCR7-PerCPCy5.5, CD27-PECy7, CD4-APC,
CD127-BV421, CD8-BV510, CD3-BV605, CD25-BV650
and CD45RA-BV786. Panel 3: CD38-FITC, BCMA-PE,
CD24-PerCPCy5.5, IgD-PECy7, CD20-APC, CD27-
BV421, IgM-BV510, CD138-BV605, CD3-BV650, CD56-
BV650 and CD19-BV711. For the ex vivo depletion
assay, a different panel was used to measure NK cells
and plasma cells/plasmablast in one panel as follows.
Panel: CD38-FITC, CD138-PE, IgD-PECy7, CD20-APC,
Live-Dead/Near-IR, CD27-Pacific Blue, CD3-BV605,
CD56-BV650, and CD19-BV711. All antibodies were
purchased from BD Bioscience except for the following:
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CD27-BV421, CD138-PE, CD56-BV650, BCMA-PE
(Biolegend) and BDCA2-VioBlue (Miltenyi). For the
analysis of CD38 expression on PBMC, CD38-FITC
(Catalog number: CYT-38F2) was purchased from Cytog-
nos (Salamanca, Spain). In the depletion assay, CD38 ex-
pression was analyzed using HuMax-003-FITC (Genmab/
Janssen R&D), a monoclonal antibody (Ab) that binds to a
different epitope than daratumumab, as described previ-
ously [22]. Isotype controls and/or FMOs (Fluorescence
Minus One) were used to determine gating boundaries.
Samples were acquired using the LSRII (BD Bioscience)
and analyzed using FlowJo software (Treestar Inc.).
Immunohistochemistry analysis (IHC)
Frozen sections of synovial biopsies were in optimal cut-
ting temperature compound and taken at 4-μm thick-
ness for evaluation of protein markers in the samples by
IHC. Tissue sections were briefly fixed in methanol, air
dried and incubated with either anti-CD38 (SP149) (Cell
Marque, Rocklin, CA, USA), anti-CD3 (2GV6) (Ventana,
Tuscon, AZ, USA) or anti-CD138 (B-A38) (Abcam,
Cambridge, MA, USA). The markers were visualized
with 3,3′-diaminobenzidine and the relative expression
of each marker was noted by JA and MS while blinded
to the specimen group information. The scoring para-
digm describes the observed expression of each marker
as either abundant, moderate or low as determined by
the number of positive cells counted within a total mag-
nification of × 100 across the entire biopsy section.
Abundant denotes strongly positive clusters of more than
20 cells in any field, moderate presence if between 5 and
20 and low if fewer than 5 cells were observed per field.
The observation in the highest density field in a sample
was recorded as the score. A pathologist, JA, reviewed
indicated areas of inflammation and hyperplasia.
Daratumumab depletion assay
PBMC samples from healthy controls and patients with
RA or SLE were thawed in complete Roswell Park
Memorial Institute medium (RPMI) and rested overnight
before the assay. Cells were then cultured in 96-well U-
bottom plates at 2.5 × 105 cells/well. Human serum
(Complement Technology, TX, USA) was applied at 10%
to the culture as a source of complement. Daratumumab
was added to the wells at concentrations indicated in the
text. Isotype control, IgG1-b12 (Genmab), a human
monoclonal Ab against an innocuous antigen (HIV1-
gp120) [22], was applied at 1 μg/ml. Cells were cultured
for 72 h before FACS, quantitative (q)PCR or branced
DNA (bDNA) analysis. CountBright absolute counting
beads (Life Technologies, CA, USA) were added to the
samples before acquisition on A flow cytometer for
quantification of each cell population. RNA was
prepared from the same culture for qPCR analysis of im-
munoglobulin J (IGJ).
RNA, qPCR and bDNA assay
RNA was prepared using Qiagen RNeasy kits (Qiagen) for
qPCR analysis of IGJ. Complementary DNA (cDNA) was
prepared using SuperScript IV VILO MasterMix and
TaqMan qPCR assay with TaqMan Universal PCR Master
Mix and samples were run on the VIIA7 instrument
(Applied Biosystems). Primers include IGJ (Hs00376160_
m1) and housekeeping genes IPO8 (Hs00183533_m1) and
GUSB (4332655). All cDNA and TaqMan reagents were
purchased from Life Technologies (CA, USA).
Alternatively, a bDNA assay was used to measure IGJ
messenger RNA (mRNA). After incubation, cells were
pelletted and triplicate wells were pooled in 100 μl PBS
and then pelleted again. Following the QuantiGene sam-
ple processing protocol for PBMC, each well was resus-
pended in 200 μl working lysis buffer and incubated for
30 min at 50–55 °C. Cell lysates were then stored at −
80 °C until needed for assay. A custom Quantigene Plex
assay containing endogenous controls TBP and HPRT1
and the target gene IGJ was run according to the manu-
facture’s manual and samples were analyzed on a Lumi-
nex 200 instrument (BioRad). For the fold-change (FC)
of IGJ mRNA in the presence of daratumumab, the rela-
tive expression level of IGJ was normalized to IGJ
mRNA in the isotype control group in some analyses.
Statistics
For high-dimensional RNA-Seq, features were considered
differentially expressed if they satisfied a 1.5-fold change
and 0.05 adjusted p value cutoff unless otherwise specified.
The Benjamini-Hochberg method was used to calculate p
values adjusted for multiple hypotheses. Fold changes
were calculated from log2(FC) estimates and reported
with a positive sign for ratios greater than 1 (log2(FC) >0)
and with a negative sign for ratios less than 1 (log2(FC)
<0). Data from flow cytometry phenotyping and depletion
experiments were analyzed using GraphPad™ Prism soft-
ware (v7). One way analysis of variance (ANOVA) with
Tukey’s test for multiple comparisons was performed to
compare cohorts and cell types.
Results
The expression of plasma cell/plasmablast differentiation
and survival-related genes is increased in synovial
biopsies from various stages during RA progression
The involvement of CD38 and plasma cell/plasmablast-re-
lated genes in RA disease progression was evaluated by
obtaining synovial tissue biopsies from patients with arth-
ralgia, UA and early and established RA. Transcriptomics
analysis by RNA-Seq in synovial tissue biopsies from
healthy donors (n = 28) and patients with OA (n = 15),
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ACPA+ rheumatoid factor (RF)+ arthralgia (n = 10), UA
(n = 6), early RA (n = 57), and established RA (n = 95)
revealed significantly higher CD38 expression as early
as the arthralgia stage (compared to healthy controls,
fold change (FC) = 4.5, P = 2.50E-04, Fig. 1a, Table 1)
prior to established RA development. This trend
continued in the patients with early (FC = 11.2, P = 3.
11E-8) and established RA (FC = 8.5, P = 3.03E-17)
(Fig. 1a, Table 1). Since specific transcription factors are
essential for plasma cell differentiation, high antibody
production and plasma cell homing to the bone
marrow, we next examined the expression of X-box
binding protein 1 (XBP1), interferon regulatory factor 4
(IRF4) and PR domain zinc finger protein 1 (PRDM1).
As predicted, this analysis showed significantly higher
expression of XBP1, IRF4 and PRDM1 in synovial tis-
sues from patients with UA, early RA and established
RA compared to patients with OA and healthy controls
(Fig. 1b). In addition, XBP1 was also significantly up-
regulated in arthralgia samples (FC = 2.97, P = 1.04E-
03). Furthermore, as IgJ is highly enriched in
plasmablasts and plasma cells [23] while BAFF (also
known as TNFSF13B) is important for plasma cell sur-
vival [24] we also analyzed their expression. The data
demonstrated that both IGJ and TNFSF13B are up-
regulated in synovial biopsies from all stages of the dis-
ease, including arthralgia, UA, early RA and established
RA (Fig. 1c and Table 1). Taken together, these data
show increased expression of plasma cell/plasmablast
differentiation and survival-related genes, indicating the
involvement of these cells in the progression from
asymptomatic arthralgia to established RA.
Plasma cells are present at higher frequency in PBMC
from patients with SLE than from patients with RA and
healthy donors
To evaluate the possibility of specifically targeting CD38
and plasma cells in patients with autoimmune disease, we
evaluated the expression of CD38 across a spectrum of im-
mune cell subpopulations in human PBMC samples. We
used CD56 to gate out NK cells and CD3 to gate out T
cells in the lymphocyte gate, and focused on CD19low/mid
Fig. 1 Plasma cell/plasmablast-related gene expression is increased at different stages of disease progression to rheumatoid arthritis (RA).
RNA-sequencing was performed on biopsies from healthy tissue, and tissue from patients with osteoarthritis (OA), arthralgia, undifferentiated
arthritis (UA), early RA and established RA (Est RA). a CD38 expression stratified by disease group/stage. b Transcription factors XBP1, IRF4, and
PRDM1 mRNA were measured in synovial biopsies from different disease groups. c Plasma cell/plasmablast survival-related genes IGJ and TNFSF13B
expression in synovial biopsies from different disease groups. *Statistically significant difference compared to healthy tissue (all graphs) (adjusted P< 0.05)
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to analyze plasma cells and plasmablasts. As shown in
Fig. 2a, plasma cells are defined as
CD3−CD56−CD19low/midCD20−CD27hiCD38hiCD138+,
whereas plasmablasts are CD3−CD56−CD19low/
midCD20−CD27hiCD38hiCD138− lymphocytes. Detailed
analysis shows that the proportion of plasma cells
among lymphocytes are significantly elevated in SLE
patients compared with healthy controls and patients
with RA (Fig. 2a and b), consistent with previous
studies [25]. A similar proportion of plasmablasts is
observed among healthy donors and those with SLE
or RA (Fig. 2a and c). We further used IgD and
CD27 to analyze CD19hi B cells, namely class-
switched memory B cells (CD27+IgD−), non-class-
Table 1 Fold change and adjusted P values for comparison of genes compared in tissues from patients with disease and from
healthy controls (see Fig. 1)














OA-healthy 1.31 0.76 1.17 0.95 1.34 0.54 1.50 0.49 1.23 0.86 1.36 0.68
Arthralgia-healthy 4.55 2.50E-04 24.52 5.34E-04 3.48 2.27E-06 2.97 1.04E-03 2.30 0.11 1.23 0.62
UA-healthy 11.84 3.10E-06 516.33 1.86E-07 4.40 1.00E-05 4.35 4.45E-04 6.96 2.74E-03 4.75 1.18E-03
Early RA-healthy 11.20 3.11E-18 123.34 2.02E-15 3.95 1.79E-15 4.44 2.93E-12 8.42 7.15E-11 3.99 8.37E-09
Est. RA-healthy 8.50 3.03E-17 81.75 3.15E-15 3.83 6.63E-17 3.62 5.14E-11 6.33 8.30E-10 3.31 6.15E-08
































































































































































Fig. 2 CD38 expression on immune cells in peripheral blood mononuclear cells (PBMC) from healthy donors and patients with systemic lupus
erythematosus (SLE) or rheumatoid arthritis (RA). a Gating strategy for plasma cells and plasmablasts in PBMC samples. Plasma cells are gated as live
singlet lymphocytes, CD3−CD56−CD19low/midCD20−CD38hiCD27hiCD138+. Plasmablasts are gated as live singlet lymphocytes, CD3−CD56−CD19low/
midCD20−CD38hiCD27hiCD138−. CD19hi B cells are separated into naïve B cell (IgD+CD27−), non-class-switched memory B cell (CD27+IgD+), class-switched
memory B cell (CD27+IgD−) and CD27− memory B cell (CD27−IgD−). b Percentage of CD27hiCD38hiCD138+ plasma cells in total lymphocytes from
PBMCs from healthy controls and patients with SLE or RA. c Percentage of CD27hiCD38hiCD138− plasmablasts in total lymphocytes from PBMCs from
different groups. d-f Percentage of class-switched memory cell (d), CD27− memory B cell (e), and non-class-switched memory B cell (f) in total
lymphocytes. g Quantification of CD38 MFI in naïve B cell, non-class switched memory cell, class-switched memory cell, CD27− memory cell, plasma cells
and plasmablasts
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switched memory B cells (CD27+IgD+), CD27−
memory B cells (CD27−IgD−) and naïve B cells
(CD27−IgD+) (Fig. 2a, right panel). The proportion
of class-switched memory cells, non-class-switched
memory cells and CD27− memory B cells was
similar among healthy donors and patients with SLE
or RA (Fig. 2d-f ). In addition, more detailed analysis
showed that plasma cells and plasmablasts display
significantly higher CD38 surface expression levels
compared to naïve B cells and all memory B cell
subsets, measured by mean fluorescence intensity
(MFI) (Fig. 2g). In contrast, CD56+CD16+ NK cells,
CD11c+ DC and BDCA2+ pDC showed intermediate
CD38 expression (Fig. 3a), whereas both naïve T
cells and central/effector memory T cells showed
very low CD38 expression (Fig. 3b). Consistent with
studies in patients with MM [26], about 10% of Treg
have high CD38 expression (Fig. 3c and d). The sig-
nificantly higher CD38 expression on plasma cells
and plasmablasts compared to other immune cells
suggests the potential for selectively depleting these
cells with an anti-CD38 monoclonal therapeutic anti-
body for treatment of patients with RA and SLE.
CD38 is expressed predominantly on plasma cells present
in synovial biopsies from patients with early RA
To evaluate CD38 protein expression in synovial biop-
sies from patients with early RA, we performed immu-
nohistochemistry analysis. In treatment-naïve patients
with early RA, CD38 stained cells were very abundant in
synovial biopsies where inflammatory cell infiltration
occurs. As shown in Fig. 3a, CD38 stained cells were ob-
served in the same region as either CD3 stained cells or
CD138 stained cells. Synovial samples from five of the
nine patients with early RA in our analysis had abundant
CD3, CD38 and CD138 stained cells, indicating high T
cell and plasma cell infiltration in the synovial biopsies
(Fig. 4a and data not shown). Synovial samples from two
of the nine patients had abundant T cell staining but few
CD38+ and CD138+ cells (Fig. 4b and data not shown).
In these tissues, CD3+ T cells were in the same region as
cells that displayed lighter CD38 staining than plasma
cells. Samples from two patients had very little staining
for CD3, CD38 or CD138 (Fig. 4c and data not shown).
Samples from these patients did not show immune cell
infiltration and may represent a pauci-immune/fibroid
pathotype [27]. This finding indicates that plasma cells
and T cells were present in synovial tissues from a sub-
population of patients with early RA.
Daratumumab depletes plasma cells and plasmablasts
ex vivo in PBMC from patients with RA and SLE
Daratumumab is a depleting anti-CD38 monoclonal
antibody, which has been approved for the treatment of
MM [14, 15, 26]. Here we sought to examine if daratu-
mumab would deplete plasma cells and plasmablasts
present in PBMCs from patients with SLE and RA,
hence providing a rationale for its therapeutic use in
plasma cell-dependent autoimmune diseases. Daratumu-
mab has shown complement-dependent cytotoxicity and
antibody-dependent cell-mediated cytotoxicity effects in




Fig. 3 CD38 expression on myeloid, natural killer (NK) and T cells in peripheral blood mononuclear cells (PBMC) from healthy donors and patients
with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). a Quantification of CD38 MFI on CD56+CD16+ NK cells, CD11c+ classical
DC, and BDCA2+ plasmacytoid dendritic cells (DC). b Quantification of CD38 MFI on CD45RA+ naïve T cells, CD62LhiCD27hiCCR7+CD45RA− central
memory T cells (TCM) and CD62L
−CD45RA− effector memory T cell (TEM). c Representative fluorescence-activated cell sorting (FACS) plot of CD38
expression on CD4+CD127lowCD25hi T regulatory cells (Tregs). d Proportion of the CD38bri subset in peripheral Tregs from healthy controls and
donors with SLE or RA
Cole et al. Arthritis Research & Therapy  (2018) 20:85 Page 7 of 14
or RA and from healthy donors were incubated with dara-
tumumab at different concentrations for 72 h before
FACS analysis. Given the small number of plasma cells
and plasmablasts in cell culture, we first combined plasma
cells and plasmablasts into one population to gain enough
events. Thus, we focused on CD3−CD56−CD19low/
midCD20−CD27hiCD38hi lymphocytes, which represent
both populations as shown in Fig. 5a. Our analysis shows
that daratumumab depletes combined plasma cell/
plasmablast populations in patients with SLE or RA and
in healthy donors in a dose-responsive manner (Fig. 5a-c).
In addition, we specifically focused on plasma cells alone
using CD3−CD56−CD19low/midCD20−CD27hiCD138hi to
avoid any complexity due to daratumumab-induced CD38
down-regulation as reported on MM cells [28]. Data show
that daratumumab depletes plasma cells in patients with
SLE or RA and in healthy donors in a dose-dependent
manner (Additional file 1: Figure S1A-C). Furthermore,
CD38 is down-regulated on the remaining plasma cells in
a dose-dependent manner. The highest concentration of
daratumumab (1 μM) induces CD38 down-regulation by
~ 10-fold ex vivo (Additional file 1: Figure S1D-E), to a
similar degree as daratumumab-induced CD38 decrease
on MM cells in patients after 10 infusions [28]. Similarly,
daratumumab also induced CD38 down-regulation on NK
cells (Additional file 1: Figure S1F-G), although NK cell
depletion is only observed in some donors bearing a larger
number of NK cells in the assay (data not shown).
Fig. 4 Immunohistochemistry analysis (IHC) of CD38 expression in synovial tissue biopsies from patients with early rheumatoid arthritis (RA).
a Representative IHC of tissue sections with abundant CD3, CD38 and CD138 staining. b Representative IHC of tissue sections with abundant CD3
but sparse CD38 and CD138 staining. c Representative IHC of tissue sections with rare CD3, CD38 and CD138 staining. All images are shown at ×
20 with 100-μM scale bar in each image. Data shown represent synovial biopsies from nine patients with early RA
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However, daratumumab had no significant dose-
dependent impact on memory B cells, including non-
class-switched memory B cells, class-switched memory B
cells or CD27− memory B cells, except that all memory
cell subsets were slightly elevated compared to isotype
control, independent of the concentration of
daratumumab (Fig. 5d-g). Likewise, no significant
depletion or CD38 down-regulation was observed on total
CD3+ T cells or CD14+ monocytes in the same assay
(Additional file 2: Figure S2). The data indicate that
plasma cell/plasmablast are the major target cells of
daratumumab depletion ex vivo.
IGJ is highly enriched in plasma cells [23]. A previous
study showed IGJhi as a biomarker for non-responders
to rituximab treatment in patients with RA because






Fig. 5 Dose-dependent depletion by daratumumab of plasma cells and plasmablasts from peripheral blood mononuclear cell (PBMC) samples
ex vivo. a Representative fluorescence-activated cell sorting (FACS) plot of combined plasma cells/plasmablasts. Shown is pre-gated on live singlet
CD3−CD56−CD19low/midCD20− lymphocytes. From left to right, plot shows the representative plasma cell/plasmablast population at 1 μg/ml
isotype control, 0.0003 μg/ml daratumumab, 0.01 μg/ml daratumumab and 1 μg/ml daratumumab (Dara), respectively. Number in the quadrant
shows absolute number of CD27hiCD38hi plasma cells-plasmablasts in each condition at 72 h post-culture. b Quantification of plasma cell/plasmablast
number at 72 h post-culture with isotype control or daratumumab at indicated concentrations. c Dose-response of plasma cell/plasmablast depletion
by daratumumab in all donors with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) and healthy donors combined. d Representative
FACS plot of CD27−IgD− memory B cell, CD27+IgD− class-switched memory B cell and CD27+IgD+ non-class-switched memory B cell at 72 h
post-culture in the presence of daratumumab at each indicated concentration. Number in the quadrant shows absolute number of each memory B
cell subset. e-g Slight increase in non-class-switched memory B cell (e), CD27+ class-switched memory B cell (f) and CD27− memory B cell (g)
compared to isotype control at each indicated concentration. For each individual donor at each daratumumab concentration, triplicate wells were
combined for quantification in a, b and d and then normalized to isotype control in c and e-g Data shown represent four healthy controls, five donors
with SLE and four with RA
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Our analysis also shows higher IGJ mRNA in synovial
biopsies from patients during RA progression (Fig. 1c).
We hypothesized that IGJ mRNA may serve as a poten-
tial pharmacodynamic biomarker for daratumumab
treatment. We measured IGJ mRNA in the same sam-
ples from depletion assays in parallel with FACS as
shown above (Fig. 5a-c). As expected, there was positive
correlation between the number of plasma cells and IGJ
mRNA at both baseline (Fig. 6a, isotype control) and in
the presence of all daratumumab concentrations tested
ex vivo (Fig. 6b). More importantly, analysis showed that
daratumumab treatment down-regulates IGJ in PBMC
samples from healthy donors and from patients with
SLE or RA in a dose-responsive manner (Fig. 6c-e).
There was positive correlation between the depletion ef-
ficacy measured by plasma cell count and IGJ mRNA
(Fig. 6f ), even though there was no significant correl-
ation between the plasma cell count at baseline and the
maximal extent of IGJ mRNA down-regulation by dara-
tumumab (Fig. 6g). Taken together, our data show that
daratumumab effectively depletes plasma cells/plasma-
blasts in SLE, RA and healthy PBMC samples ex vivo
and IGJ mRNA may serve as a pharmacodynamic
biomarker.
Discussion
CD38 has been extensively studied as a target for the
treatment of patients with MM and daratumumab has
shown outstanding efficacy in this patient population
[14–16]. However, the application of this potential
plasma cell/plasmablast-depleting agent such as daratu-






Fig. 6 Quantitative PCR analysis shows dose-dependent IGJ down-regulation by daratumumab ex vivo. a Positive correlation between IGJ mRNA
and plasma cell count at baseline of isotype control. b Positive correlation between IGJ mRNA and plasma cell count at different daratumumab
concentrations ex vivo. c-e IGJ expression at different daratumumab concentration at 72 h post-treatment in healthy controls (c, n = 7) and
patients with systemic lupus erythematosus (SLE) (d, n = 4) and rheumatoid arthritis (RA) (e, n = 4). Relative expression of IGJ in the isotype control
was normalized to 1 (shown as dashed line). f Positive correlation between normalized IGJ mRNA fold change and plasma cell count fold change
compared to isotype control at various daratumumab concentrations. g Correlation between the number of plasma cells at baseline and the
maximal IGJ mRNA down-regulation. Data shown in a, b, f and g represent two donors with SLE and sixhealthy control donors
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been studied, especially in early stage disease. In this
study, using integrative analysis of synovial tissue biop-
sies obtained from different stages of RA disease and
PBMC, we have shown that 1) CD38 and plasma cell/
plasmablast-related genes are up-regulated in ACPA+RF+
arthralgia and UA disease stages before the onset of RA;
2) CD38 is expressed at the highest level on plasma cells
compared to other immune cell populations in RA, SLE
and healthy donors in the peripheral blood; and most
importantly 3) daratumumab effectively depletes plasma
cells/plasmablast in SLE and RA PBMC ex vivo.
Plasma cells and autoantibodies are important in RA
pathogenesis as indicated by ACPA production in pa-
tients with RA and the correlation between ACPA titer
and disease activity score [30]. Staining for CD38 has
also been observed in synovial biopsies from patients
with established RA [31]. However, there has been no
focus on subjects with pre-RA disease (arthralgia and
UA) and treatment-naïve patients with early RA. Herein,
we showed that the expression of major genes related to
plasma cells and plasmablast development and survival
is significantly heightened in synovial biopsies from do-
nors with arthralgia and UA compared to healthy donors
and those with OA. These include CD38, XBP1, IGJ and
TNFSF13B, IRF4 and PRDM1, and their up-regulation is
observed in synovial biopsies from donors with UA,
early RA and established RA. These data indicate that
even before the onset of clinically classifiable RA disease,
there may be autoantibody-producing plasma cells in the
joints, which may drive the progression of the disease.
This is in keeping with previous data showing the pres-
ence of autoreactive plasma cells in synovial ectopic
lymphoid structures (ELS) driving local production of
ACPA antibodies [32]. In addition, in the same paper it
was shown that ELS act as self-sustained survival niches
for plasma cells, as ELS-positive but not ELS-negative
synovial tissue displayed a sustained capacity to produce
class-switched ACPA when transplanted into SCID mice
in the absence of new cells infiltrating the grafts [32].
Thus, the functional presence of plasmablasts/cells in
synovial niches together with the high expression of
genes involved in their development and survival indi-
cates that therapeutic targeting of antibody-producing
plasma cells/plasmablasts with these molecules, in par-
ticular CD38, could be a viable strategy for disease inter-
vention in patients with arthralgia to prevent
progression to established RA. This notion is further
supported by recent observations demonstrating in-
creased levels of circulating IgA plasmablasts in sero-
positive (ACPA+) subjects without any clinical signs of
disease [33]. The absence of IRF4 and PRDM1 up-
regulation in the joints of patients with arthralgia may
indicate three possibilities. First, there are not yet
enough plasma cells in the joints of these patients to
allow for the detection of these changes in transcription
factor expression compared to healthy controls. Second,
modest changes in these master transcription factors
may indeed reflect a decent number of plasma cells/plas-
mablasts to initiate the disease progression. Third, at this
early stage of the disease progression, plasma cells/plas-
mablasts may migrate into the joints from the periphery
and de novo differentiation/development has not yet oc-
curred. Further studies are warranted to determine if
plasma cells/plasmablasts are the earliest detectable im-
mune cells in the joints of arthralgia patients and justify
the clinical testing of CD38-depleting agents in this
patient population.
The above reported IHC results indicate that plasma
cells and T cells are dominant in the synovial tissues of
treatment-naïve patients with early RA. The data also
show that CD38 staining is in the same region as cells that
are neither T cells nor plasma cells, which could be mac-
rophages. Therefore, CD38-targeted therapeutics may de-
crease other pathogenic cells in the synovial tissue while
preferentially depleting plasma cells. More careful moni-
toring of clinical data is warranted to determine the target
immune populations in patients with RA or SLE.
We have also shown that plasma cells and plasma-
blasts can be effectively depleted ex vivo in PBMC sam-
ples from donors with SLE or RA and healthy donors.
This provides the rationale for depleting the plasma
cells/plasmablasts specifically in patients with RA and
SLE. NK cells have been reported to decrease signifi-
cantly in patients with cancer treated with daratumumab
[34]. Although it is possible that NK cells become de-
pleted in patients with RA, we saw more robust plasma
cell/plasmablast depletion ex vivo in donors with SLE or
RA and healthy donors. Therefore, we may be able to
find a dose of daratumumab, potentially much lower
than the clinical dose in MM, which selectively depletes
plasma cells/plasmablasts without significantly affecting
NK cells in the same patient. The remarkable decrease
in plasma cells and plasmablasts in peripheral blood
may serve as a surrogate biomarker for the pharmacody-
namic efficacy measurement. Furthermore, the down-
regulation of IGJ mRNA confirms the depletion of
plasma cells upon daratumumab treatment. The dose-
response with daratumumab shown in donor PBMCs
suggests IGJ as a potential surrogate biomarker for
plasma cell depletion. Consistent with previous studies
showing IGJ as a hallmark gene for plasma cells [23], we
observed positive correlation between the number of
plasma cells and IGJ mRNA in all conditions ex vivo
(Fig. 6a and b). The positive correlation between the
changes in plasma cell number and change in IGJ
mRNA reinforces the notion of using IGJ mRNA as a
pharmacodynamic biomarker for daratumumab (Fig. 6f ).
The donors with more plasma cells at baseline and thus
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higher IGJ mRNA had more readily measurable dose re-
sponse to daratumumab-mediated depletion ex vivo than
the donors with fewer plasma cells and lower IGJ mRNA
(Figs. 5 and 6, and data not shown). However, the lack of
correlation between the number of plasma cells and
maximal IGJ mRNA down-regulation level may be due
to the high antibody-dependent cellular cytotoxicity
(ADCC) activity of daratumumab and the small number
of cells, and therefore very efficient depletion in all do-
nors ex vivo. Nevertheless, the dose response suggests
that IGJ mRNA level may also serve as a patient stratifi-
cation marker as we enter the era of personalized medi-
cine, i.e. only patients with higher IGJ mRNA and thus a
more plasma cells may be treated with daratumumab or
other anti-CD38 therapeutic antibodies. The application
of IGJ as biomarker can potentially facilitate clinical de-
velopment of anti-CD38 in autoimmune diseases. This is
consistent with the finding that identified IGJhi as a
biomarker in patients with RA who may not benefit
from B cell depletion therapy with rituximab [29].
Plasma cell depleting agents such as daratumumab may
prove efficacious in this patient population.
Given the high unmet need for deeper and long-lasting
responses in RA and SLE, it is important to develop ther-
apies with more specificity for patient subpopulations
based upon selective dysregulated pathways. Patient strati-
fication based on plasma cell and plasmablast analysis may
prove more efficacious in clinical testing of anti-CD38
therapeutic agents in RA and SLE. Studies are warranted
to determine if daratumumab or other anti-CD38
antibody-based therapies have efficacy in pre-disease states,
such as arthralgia and UA, by delaying or preventing the
clinical course of disease progression. In summary, our re-
sults indicate that plasma cell/plasmablast depleting mech-
anisms can be used not only for the treatment of
established RA but also for the prevention of the disease
progression to RA. Furthermore, a plasma cell/plasmablast
depleting agent, such as daratumumab, may also show effi-
cacy in other autoantibody-dependent indications, like
SLE, IgG4-related disease, multiple sclerosis, myasthenia
gravis, primary Sjogren’s syndrome and so on. Finally, in a
manner analogous to pre-RA disease, SLE is also consid-
ered to have a natural course of evolution with pre-disease
state(s) exhibiting asymptomatic autoimmunity [35]. An
anti-CD38 or other plasma cell/plasmablast targeting agent
may also prevent/delay the progression of asymptomatic
autoimmunity to a clinically classifiable lupus stage.
Conclusions
In conclusion, using integrative analysis of synovial tis-
sue biopsies and PBMC, we have shown that (1) CD38
and plasma cell/plasmablast-related genes are up-
regulated in ACPA+RF+ arthralgia and UA disease stages
before the onset of RA; (2) CD38 is expressed at the
highest level on plasma cells in the peripheral blood
compared to other immune cell populations in donors
with RA or SLE and healthy donors; (3) daratumumab,
an approved cancer drug, effectively depletes plasma
cells/plasmablasts in SLE and RA PBMC ex vivo. The
data suggest that daratumumab and other CD38-
targeting therapeutic antibodies may prove efficacious in
prevention at the pre-disease stage and in the treatment
of plasma-cell-rich established RA and SLE.
Additional files
Additional file 1: Figure S1. Dose-dependent ex vivo depletion of
plasma cells by daratumumab in PBMC samples. (A) Representative FACS
plot of combined plasma cells. Pre-gated on live singlet
CD3−CD56−CD19low/midCD20−lymphocytes. From left to right, plot shows
the representative plasma cell population (CD27hiCD138+) at 1 μg/ml
isotype control, 0.0003 μg/ml daratumumab, 0.01μg/ml daratumumab
and 1μg/ml daratumumab, respectively. Number in the quadrant shows
the absolute number of plasma cells at each condition. (B) Quantification
of plasma cells at 72 h post-culture with isotype control or daratumumab
(Dara) at indicated concentrations. (C) Dose-response of plasma cell
depletion by daratumumab in combined samples from patients with SLE
or RA and healthy controls. (D) Representative quantification of CD38 MFI
on remaining plasma cells at 72 h post-culture with isotype control or
daratumumab at indicated concentrations. (E) Dose-response of CD38
down-regulation on plasma cells by daratumumab in all samples combined
as in C-D. For each individual donor at each daratumumab concentration,
triplicate wells were combined for quantification in B and D and then
normalized to isotype control in C and E. (F) Representative quantification of
CD38 MFI on CD56+CD16+ NK cells at 72 h post-culture with isotype control
or daratumumab at indicated concentrations. (G) Dose response of CD38
MFI down-regulation on NK cells by daratumumab in patients with SLE or
RA and healthy controls combined. Data shown represent four patients with
SLE, four with RA and four healthy controls. (PDF 401 kb)
Additional file 2: Figure S2. Daratumumab has no impact on T cells
and monocytes ex vivo. (A) Total number of CD3+ T cells in each
daratumumab concentration at 72 h post-treatment. (B) Quantification of
CD38 MFI on CD3+ T cells at 72 h post-culture with isotype control or
daratumumab at indicated concentrations. (C) Total number of CD14+
monocytes in each daratumumab concentration at 72 h post-treatment.
(D) Quantification of CD38 MFI on CD14+ monocytes at 72 h post-culture
with isotype control or daratumumab at indicated concentrations. Data
shown represent four patients with SLE, six with RA and six healthy
control donors. (PNG 2127 kb)
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